Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
IMSE, TU Munich (Biometry)
WiSP Wissenschaftlicher Service Pharma GmbH
German CLL Study Group
Information provided by (Responsible Party):
Stephan Stilgenbauer, University of Ulm
ClinicalTrials.gov Identifier:
NCT01392079
First received: June 28, 2011
Last updated: May 27, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)